ERBB2 and breast cancer: Moreover, data from the randomized TH3RESA trial, which compared T-DM1 vs. treatment of physician choice for pretreated metastatic HER2+ BC patients, confirmed that patients with higher ERBB2 mRNA levels benefited more from T-DM1 than patients with lower ERBB2 mRNA levels [24].